Qdot™ 605 ITK™ Streptavidin Conjugate Kit
Qdot™ 605 ITK™ Streptavidin Conjugate Kit
Invitrogen™

Qdot™ 605 ITK™ Streptavidin Conjugate Kit

The Qdot™ 605 ITK™ Streptavidin Conjugate Kit provides the Qdot™ streptavidin conjugate as 250 μL of a 2 μM solution.Read more
Have Questions?
Catalog NumberQuantity
Q10001MP1 kit
Catalog number Q10001MP
Price (EUR)
757,65
Online Exclusive
1.010,00
Save 252,35 (25%)
Each
Add to cart
Quantity:
1 kit
Price (EUR)
757,65
Online Exclusive
1.010,00
Save 252,35 (25%)
Each
Add to cart
The Qdot™ 605 ITK™ Streptavidin Conjugate Kit provides the Qdot™ streptavidin conjugate as 250 μL of a 2 μM solution. Unlike the Qdot™ streptavidin conjugates, the Qdot™ ITK™ streptavidin conjugates have the streptavidin covalently attached to the inner amphiphilic coating without a PEG linker. These Qdo™ conjugates can be used for binding biotinylated probes. The kit also includes 30 mL of Qdot™ incubation buffer.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Concentration2 μM
Product TypeStreptavidin Conjugate (fluorescent)
Quantity1 kit
Shipping ConditionRoom Temperature
ConjugateQdot 605
Product LineITK, Qdot
Unit SizeEach
Contents & Storage
Store in refrigerator (2–8°C).

Frequently asked questions (FAQs)

I am getting very high background with my Qdot streptavidin conjugate. Do you have any suggestions?

Here are some suggestions: Use the Qdot Incubation Buffer (Cat. No. Q20001MP). The included buffer is formulated specifically for improved signal-to-background ratios in most immunolabeling applications using the Qdot streptavidin conjugates. Alternate buffers may result in more variable staining and, in particular, may increase background staining. However, some specific applications may require other buffer conditions. Please see the protocol "Double-labeling Using Qdot Streptavidin conjugates."
Determine if the sample has a high level of endogenous biotin. Block the sample using an avidin-biotin pre-blocking step.
If you have used the Qdot Incubation Buffer and still get high nonspecific background, then it may be necessary to check other steps of your procedure. Blocking the sample with BSA or normal animal serum will generally decrease nonspecific binding of both antibodies and Qdot streptavidin conjugates. It is a good practice to dilute your primary and secondary antibodies in the blocking buffer. Some tissues such as spleen and kidney sections may contain endogenous biotin, which may contribute to non-specific signal. Endogenous biotin can be blocked with an avidin/biotin blocking kit (Cat. No. E21390).
Grainy staining or clumps of fluorescent material appear in the background.
Occasionally the BSA within the Qdot Incubation Buffer shows slight aggregation over time. It is necessary to remove this aggregate prior to labeling the sample with the Qdot streptavidin conjugate. Spin down the incubation mixture before addition to the sample. This can be accomplished by spinning the samples in a benchtop centrifuge (Eppendorf 5415) at 5,000 x g for 2 minutes. The material can also be passed over a 0.2 µm spin filter unit before you add it to the sample for staining to remove microscopic precipitates. If you are using a buffer that is different than the Qdot Incubation Buffer, this behavior can often be attributed to higher levels of NaCl or other salts in the incubation buffer, and may not be easily fixed with filtration. In this case, reduce the overall salt concentration.
Optimize concentration of biotinylated secondary antibodies.
Optimizing specific signal can often be achieved by adjusting the level of biotinylated antibody used instaining. High levels of biotinylated antibody are necessary to obtain specific labeling, but overly high levels will contribute to nonspecific binding of the antibody to the sample. Nonspecifically bound biotinylated antibody will bind to the Qdot streptavidin conjugate, resulting in higher staining of the background.
Optimize concentration of Qdot streptavidin conjugate.
Just as titration of primary and secondary antibodies is necessary to achieve optimal specific signal in immunolabeling applications, the level of the final probe should be optimized for each conjugate. In general, concentrations at or slightly below saturation should have the optimal signal-to-background ratio, while concentrations substantially higher than saturation will compromise the assay with higher background levels.

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

I am getting no signal with my Qdot streptavidin conjugate. What should I do?

Here are some suggestions:

Confirm imaging/detection setup suitability.
Make sure that you are using an appropriate filter set to detect the signal. Please consult Table 1 in the Qdot Biotin User Manual for a list of appropriate and optimal filters.
Check to see that Qdot conjugate is fluorescing using an alternative light source.
Qdot conjugates will normally fluoresce brightly under a hand-held ultraviolet lamp (long wave, such as the type used to visualize ethidium bromide on agarose gels). Although we have not seen pronounced loss of fluorescence of these materials under any storage conditions that we have investigated, we have not been able to examine all storage conditions. If the Qdot product does not appear to fluoresce under the long wave UV excitation, please contact Technical Support at techsupport@qdots.com. For a microscope, perform a spot test: place a small droplet (2 to 5 µL) of the quantum dot solution onto a clean slide (no coverslip) and examine under the appropriate filter set at low magnification.
Confirm the specificity and titer of primary antibody.
Make sure the antibody will recognize the intended targets. Make sure there is sufficient primary antibody bound to the targets. This verification can be performed by ELISA-based capture of the antigen of interest, or by other techniques that can be found in lab manuals such as the Current Protocols in Immunology.
For Qdot streptavidin conjugates, confirm biotinylation of antibody.
Make sure your antibodies are effectively biotinylated. It may be necessary to independently adjust the concentration of both the primary and secondary antibodies used in the assay to obtain optimal signal and minimal background.
PAP pen ink may quench signal.
Use an alternate method for isolating target areas on the slide. If your protocol requires the use of a PAP pen, we recommend the ImmEdge Hydrophobic Barrier Pen (Cat. No. H-4000) from Vector Labs.

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

What is the best way to remove white precipitate from my ITK Qdot nanocrystals?

Spinning your ITK Qdot nanocrystals at approximately 3,000 rpm for 3-5 minutes should remove the white precipitate from the supernatant. Use the supernatant immediately.

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

I see a white precipitate in my ITK Qdot nanocrystals; should I be concerned?

The precipitate in the organic ITK Qdot nanocrystals occurs with some frequency. The ITK Qdot nanocrystals sometimes include impurities that show as a white precipitate.

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

Why do my Qdot nanocrystals appear to be blinking?

Blinking is an inherent property of quantum dots; in fact, all single-luminescent molecules blink, including organic dyes. The brightness and photostability of Qdot nanocrystals makes the blinking more visibly apparent. Under higher energy excitation, Qdot nanocrystals blink even faster.

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

Citations & References (23)

Citations & References
Abstract
Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots.
Authors:Giepmans BN, Deerinck TJ, Smarr BL, Jones YZ, Ellisman MH
Journal:Nat Methods
PubMed ID:16179920
'The importance of locating proteins in their context within cells has been heightened recently by the accomplishments in molecular structure and systems biology. Although light microscopy (LM) has been extensively used for mapping protein localization, many studies require the additional resolution of the electron microscope. Here we report the application ... More
Analysis method for measuring submicroscopic distances with blinking quantum dots.
Authors:Lagerholm BC, Averett L, Weinreb GE, Jacobson K, Thompson NL
Journal:Biophys J
PubMed ID:16861265
'A method is described that takes advantage of the intermittency ("blinking") in the fluorescence of quantum dots (QDs) to measure absolute positions of closely spaced QDs. The concept is that even if two QDs are separated by only tens of nanometers, the position of each QD is resolvable if the ... More
In vitro sliding of actin filaments labelled with single quantum dots.
Authors:Månsson A, Sundberg M, Balaz M, Bunk R, Nicholls IA, Omling P, Tågerud S, Montelius L
Journal:Biochem Biophys Res Commun
PubMed ID:14733939
'We recently refined the in vitro motility assay for studies of actomyosin function to achieve rectified myosin induced sliding of actin filaments. This paves the way, both for detailed functional studies of actomyosin and for nanotechnological applications. In the latter applications it would be desirable to use actin filaments for ... More
Quantitative comparison of intracellular unpacking kinetics of polyplexes by a model constructed from quantum dot-FRET.
Authors:Chen HH, Ho YP, Jiang X, Mao HQ, Wang TH, Leong KW,
Journal:Mol Ther
PubMed ID:18180773
'A major challenge for non-viral gene delivery is gaining a mechanistic understanding of the rate-limiting steps. A critical barrier in polyplex-mediated gene delivery is the timely unpacking of polyplexes within the target cell to liberate DNA for efficient gene transfer. In this study, the component plasmid DNA and polymeric gene ... More
DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay.
Authors:Bailey VJ, Keeley BP, Razavi CR, Griffiths E, Carraway HE, Wang TH,
Journal:Methods
PubMed ID:20362674
'Detection of aberrant promoter hypermethylation of tumor suppressor genes can be used as a prognostic or predictive marker for carcinogenesis. Since epigenetic modifying agents are FDA approved for treatment of patients with myelodysplastic syndrome, laboratory correlative tools to monitor response to this targeted therapy are important. Methylation specific quantum dot ... More